Equal yet different: a comparative characterization of Ruthenibacterium lactatiformans and Faecalibacterium prausnitzii
- Authors: Das M.S.1, Podoprigora I.V.1, Yashina N.V.1, Senyagin A.N.1, Tokmalaev A.K.1, Orlova V.S.1, Efimov B.A.2
-
Affiliations:
- Peoples’ Friendship University of Russia (RUDN University)
- Pirogov Russian National Research Medical University
- Issue: Vol 31, No 1 (2026)
- Pages: 51-63
- Section: Reviews
- Submitted: 21.01.2026
- Accepted: 27.01.2026
- Published: 06.03.2026
- URL: https://rjeid.com/1560-9529/article/view/701378
- DOI: https://doi.org/10.17816/EID701378
- EDN: https://elibrary.ru/MKOEYK
- ID: 701378
Cite item
Abstract
The gut microbiota plays a key role in maintaining human homeostasis. Of particular interest are 2 bacterial species of the family Oscillospiraceae: the well-studied Faecalibacterium prausnitzii, with proven anti-inflammatory properties, and the recently described Ruthenibacterium lactatiformans, whose functional potential remains insufficiently investigated. Despite their phylogenetic proximity, these species differ substantially in metabolic properties, associations with pathological conditions, and probiotic potential. The work aimed to conduct a comparative analysis of the characteristics of F. prausnitzii and R. lactatiformans and their interactions with the host, as well as to summarize data on possible mechanisms underlying their influence on the development of a wide range of diseases, including inflammatory bowel diseases, cardiovascular, metabolic, neurologic, and oncologic diseases.
Studies demonstrate that reduced abundance of F. prausnitzii serves as a reliable biomarker of dysbiosis and is associated with chronic inflammatory, autoimmune, and metabolic diseases. The protective role of this bacterium is primarily related to butyrate production and immunomodulation. In contrast to F. prausnitzii, associations of R. lactatiformans with pathological conditions are inconsistent. Increased abundance of this species correlates with both pathological states (stroke, active multiple sclerosis) and periods of clinical remission in certain diseases. At the same time, in experimental models, R. lactatiformans demonstrates protective, particularly metabolic, properties.
The decrease in F. prausnitzii abundance under pathological conditions is likely explained by its sensitivity to environmental changes such as tissue acidosis and oxidative stress. In contrast, R. lactatiformans, owing to greater metabolic plasticity (ability to produce lactate and acetate) and relative aerotolerance, is capable of adapting to these unfavorable conditions.
In conclusion, we support the hypothesis that the observed changes may reflect a dynamic dysbiotic shift and potential synergism rather than competition: R. lactatiformans, acting as an adaptive substrate supplier, may contribute to restoration of conditions favorable for subsequent colonization by butyrate-producing bacteria such as F. prausnitzii. This opens new perspectives for the development of probiotic strategies based on synergistic bacterial consortia.
Full Text
About the authors
Milana S. Das
Peoples’ Friendship University of Russia (RUDN University)
Author for correspondence.
Email: milanadas@yandex.ru
ORCID iD: 0000-0001-7637-9879
SPIN-code: 5956-7634
MD
Russian Federation, MoscowIrina V. Podoprigora
Peoples’ Friendship University of Russia (RUDN University)
Email: podoprigora-iv@rudn.ru
ORCID iD: 0000-0003-4099-2967
SPIN-code: 7255-4454
MD, Cand. Sci. (Medicine), Assistant Professor
Russian Federation, MoscowNatalia V. Yashina
Peoples’ Friendship University of Russia (RUDN University)
Email: yashina-nv@rudn.ru
ORCID iD: 0000-0003-1372-5257
SPIN-code: 4340-5962
Cand. Sci. (Biology), Assistant Professor
Russian Federation, MoscowAlexsander N. Senyagin
Peoples’ Friendship University of Russia (RUDN University)
Email: senyagin-an@rudn.ru
ORCID iD: 0000-0002-4981-0149
SPIN-code: 2658-3063
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowAnatoly K. Tokmalaev
Peoples’ Friendship University of Russia (RUDN University)
Email: tokmalaev-ak@rudn.ru
ORCID iD: 0000-0001-7046-0799
SPIN-code: 1650-0831
MD, Dr. Sci. (Medicine), Professor
Russian Federation, MoscowValentina S. Orlova
Peoples’ Friendship University of Russia (RUDN University)
Email: orlova-vs@rudn.ru
ORCID iD: 0000-0001-9178-5736
SPIN-code: 8078-0470
Dr. Sci. (Biology), Professor
Russian Federation, MoscowBoris A. Efimov
Pirogov Russian National Research Medical University
Email: efimov_ba@mail.ru
ORCID iD: 0009-0003-8879-6516
SPIN-code: 3056-5899
MD, Dr. Sci. (Medicine), Professor
Russian Federation, MoscowReferences
- Chang C, Yuan X, Zhang X, et al. Gastrointestinal microbiome and multiple health outcomes: umbrella review. Nutrients. 2022;14(18):3726. doi: 10.3390/nu14183726 EDN: JSGPTN
- Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther. 2010;8(4):435–454. doi: 10.1586/eri.10.14
- Sen T, Thummer RP. The impact of human microbiotas in hematopoietic stem cell and organ transplantation. Front Immunol. 2022;13:932228. doi: 10.3389/fimmu.2022.932228 EDN: GRMLKR
- Yoo S, Jung SC, Kwak K, Kim JS. The role of prebiotics in modulating gut microbiota: implications for human health. Int J Mol Sci. 2024;25(9):4834. doi: 10.3390/ijms25094834 EDN: GXBNEQ
- Zhu B, Edwards DJ, Spaine KM, et al. The association of maternal factors with the neonatal microbiota and health. Nat Commun. 2024;15(1):5260. doi: 10.1038/s41467-024-49160-w EDN: GJLCTW
- De Filippis F, Paparo L, Nocerino R, et al. Specific gut microbiome signatures and the associated pro-inflamatory functions are linked to pediatric allergy and acquisition of immune tolerance. Nat Commun. 2021;12(1):5958. doi: 10.1038/s41467-021-26266-z EDN: JYGBCJ
- Marcos-Fernández R, Riestra S, Alonso-Arias R, et al. Immunomagnetic capture of Faecalibacterium prausnitzii selectively modifies the fecal microbiota and its immunomodulatory profile. Microbiol Spectr. 2023;11(1):e0181722. doi: 10.1128/spectrum.01817-22 EDN: XCIMEE
- Zhao L, Grimes SM, Greer SU, et al. Characterization of the consensus mucosal microbiome of colorectal cancer. NAR Cancer. 2021;3(4):zcab049. doi: 10.1093/narcan/zcab049 EDN: EYSHZV
- Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017;11(4):841–852. doi: 10.1038/ismej.2016.176 EDN: YWLKON
- Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731–16736. doi: 10.1073/pnas.0804812105
- Fitzgerald CB, Shkoporov AN, Sutton TDS, et al. Comparative analysis of Faecalibacterium prausnitzii genomes shows a high level of genome plasticity and warrants separation into new species-level taxa. BMC Genomics. 2018;19(1):931. doi: 10.1186/s12864-018-5313-6 EDN: MHBOSS
- Shkoporov AN, Chaplin AV, Shcherbakova VA, et al. Ruthenibacterium lactatiformans gen. nov., sp. nov., an anaerobic, lactate-producing member of the family Ruminococcaceae isolated from human faeces. Int J Syst Evol Microbiol. 2016;66(8):3041–3049. doi: 10.1099/ijsem.0.001143 EDN: XFKZPB
- Rampelli S, Turroni S, Mallol C, et al. Components of a Neanderthal gut microbiome recovered from fecal sediments from El Salt. Commun Biol. 2021;4(1):169. doi: 10.1038/s42003-021-01689-y EDN: RIRPRW
- Prausnitz C. Der Bacillus mucosus anaerobius. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg Abt I Orig. 1922;89:126–132.
- Hauduroy P, Ehringer G, Guillot G, et al. Dictionnaire des bactéries pathogènes: pour l’homme, les animaux et les plantes. Paris: Masson; 1937.
- Cato EP, Salmon CW, Moore WEC. Fusobacterium prausnitzii (Hauduroy et al.) Moore and Holdeman: emended description and designation of neotype strain. Int J Syst Bacteriol. 1974;24(2):225–229.
- Collins MD, Lawson PA, Willems A, et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Evol Microbiol. 1994;44(4):812–826.
- Duncan SH, Hold GL, Harmsen HJM, et al. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol. 2002;52(Pt 6):2141–2146. doi: 10.1099/00207713-52-6-2141
- Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. doi: 10.1038/nature09944
- Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996–1047. doi: 10.1111/1574-6976.12075
- Kumar S, Stecher G, Suleski M, et al. MEGA12: molecular evolutionary genetic analysis version 12 for adaptive and green computing. Mol Biol Evol. 2024;41(12):msae263. doi: 10.1093/molbev/msae263 EDN: XJLZTL
- Sumiyoshi S, Hamaguchi S, Kimura K, et al. Ruthenibacterium lactatiformans isolated from a human blood culture: a first report. BMC Infect Dis. 2024;24(1):699. doi: 10.1186/s12879-024-09606-4 EDN: YMBXJT
- Hashimoto Y, Hisatsune J, Suzuki M, et al. Elucidation of host diversity of the VanD-carrying genomic islands in enterococci and anaerobes. JAC Antimicrob Resist. 2022;4(1):dlab189. doi: 10.1093/jacamr/dlab189 EDN: IVHFHN
- Blanco G, Sánchez B, Fdez-Riverola F, et al. In silico approach for unveiling the glycoside hydrolase activities in Faecalibacterium prausnitzii through a systematic and integrative large-scale analysis. Front Microbiol. 2019;10:517. doi: 10.3389/fmicb.2019.00517 EDN: WZMXEC
- Geng P, Zhao N, Zhou Y, et al. Faecalibacterium prausnitzii regulates carbohydrate metabolic functions of the gut microbiome in C57BL/6 mice. Gut Microbes. 2025;17(1):2455503. doi: 10.1080/19490976.2025.2455503 EDN: OTULEU
- Dogra SK, Dardinier A, Mainardi F, et al. Application of computational data modeling to a large-scale population cohort assists the discovery of inositol as a strain-specific substrate for Faecalibacterium prausnitzii. Nutrients. 2023;15(6):1311. doi: 10.3390/nu15061311 EDN: EILRXH
- Huang YJ, Lewis CA, Wright C, et al. Faecalibacterium prausnitzii A2-165 metabolizes host- and media-derived chemicals and induces transcriptional changes in colonic epithelium in GuMI human gut microphysiological system. Microbiome Res Rep. 2024;3(3):30. doi: 10.20517/mrr.2024.14 EDN: HPLDND
- Guo Y, Crnkovic CM, Won KJ, et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. Drug Metab Dispos. 2019;47(3):194–202. doi: 10.1124/dmd.118.084772
- Auger S, Kropp C, Borras-Nogues E, et al. Intraspecific diversity of microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii. Int J Mol Sci. 2022;23(3):1705. doi: 10.3390/ijms23031705 EDN: RRLTQZ
- Miquel S, Leclerc M, Martin R, et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio. 2015;6(2):e00300-15. doi: 10.1128/mBio.00300-15 EDN: UOUOOR
- Hammond TC, Powell E, Green SJ, et al. Functional recovery outcomes following acute stroke is associated with abundance of gut microbiota related to inflammation, butyrate and secondary bile acid. Front Rehabil Sci. 2022;3:1017180. doi: 10.3389/fresc.2022.1017180 EDN: IYPXUA
- Li W, Li H, Wang S, et al. Regional pattern and signatures of gut microbiota in rural residents with coronary heart disease: A metagenomic analysis. Front Cell Infect Microbiol. 2022;12:1007161. doi: 10.3389/fcimb.2022.1007161 EDN: QPTVDE
- Xu H, Zhao H, Fan D, et al. Interactions between gut microbiota and immunomodulatory cells in rheumatoid arthritis. Mediators Inflamm. 2020;2020:1430605. doi: 10.1155/2020/1430605 EDN: VNNFJT
- Lee JY, Mannaa M, Kim Y, et al. Comparative analysis of fecal microbiota composition between rheumatoid arthritis and osteoarthritis patients. Genes (Basel). 2019;10(10):748. doi: 10.3390/genes10100748 EDN: ZYRXDU
- Clos-Garcia M, Ahluwalia TS, Winther SA, et al. Multiomics signatures of type 1 diabetes with and without albuminuria. Front Endocrinol (Lausanne). 2022;13:1015557. doi: 10.3389/fendo.2022.1015557 EDN: TKDFCB
- Trivieri N, Pracella R, Cariglia MG, et al. BRAFV600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies. J Exp Clin Cancer Res. 2020;39(1):285. doi: 10.1186/s13046-020-01801-w EDN: WOEOXG
- Sabater C, Calvete-Torre I, Ruiz L, Margolles A. Arabinoxylan and pectin metabolism in Crohn’s disease microbiota: An in silico study. Int J Mol Sci. 2022;23(13):7093. doi: 10.3390/ijms23137093 EDN: QKOKBI
- Jangi S, Zhao N, Hsia K, et al. Specific bacterial co-abundance groups are associated with inflammatory status in patients with ulcerative colitis. J Crohns Colitis. 2025;19(1):jjae125. doi: 10.1093/ecco-jcc/jjae125 EDN: KNQPRH
- Dias BDC, Lamarca AP, Machado DT, et al. Metabolic pathways associated with Firmicutes prevalence in the gut of multiple livestock animals and humans. Anim Microbiome. 2025;7(1):20. doi: 10.1186/s42523-025-00379-y EDN: DUFDDA
- Eckenberger J, Butler JC, Bernstein CN, et al. Interactions between medications and the gut microbiome in inflammatory bowel disease. Microorganisms. 2022;10(10):1963. doi: 10.3390/microorganisms10101963 EDN: KOYAHZ
- Testerman T, Li Z, Galuppo B, et al. Insights from shotgun metagenomics into bacterial species and metabolic pathways associated with NAFLD in obese youth. Hepatol Commun. 2022;6(8):1962–1974. doi: 10.1002/hep4.1944 EDN: CRTNEY
- Wu F, Guo Y, Wang Y, et al. Effects of long-term fasting on gut microbiota, serum metabolome, and their association in male adults. Nutrients. 2024;17(1):35. doi: 10.3390/nu17010035 EDN: BIONNE
- Kovtun AS, Averina OV, Angelova IY, et al. Alterations of the composition and neurometabolic profile of human gut microbiota in major depressive disorder. Biomedicines. 2022;10(9):2162. doi: 10.3390/biomedicines10092162 EDN: WVZGWF
- Cox LM, Maghzi AH, Liu S, et al. Gut microbiome in progressive multiple sclerosis. Ann Neurol. 2021;89(6):1195–1211. doi: 10.1002/ana.26084 EDN: AFFKGG
- Zhou X, Baumann R, Gao X, et al. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185(19):3467–3486.e16. doi: 10.1016/j.cell.2022.08.021 EDN: JFOATQ
- Becker A, Schmartz GP, Gröger L, et al. Effects of resistant starch on symptoms, fecal markers, and gut microbiota in Parkinson’s disease - The RESISTA-PD trial. Genomics Proteomics Bioinf. 2022;20(2):274–287. doi: 10.1016/j.gpb.2021.08.009 EDN: ULAIYN
- Wallen ZD, Demirkan A, Twa G, et al. Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun. 2022;13(1):6958. doi: 10.1038/s41467-022-34667-x
- Yay E, Yilmaz M, Toygar H, et al. Oral and gut microbial profiling in periodontitis and Parkinson’s disease. J Oral Microbiol. 2024;16(1):2331264. doi: 10.1080/20002297.2024.2331264 EDN: QSAGBF
- Liang S, Mao Y, Liao M, et al. Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps. Int J Biol Sci. 2020;16(1):135–146. doi: 10.7150/ijbs.37399 EDN: JVVYIS
- Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016;7(29):46158–46172. doi: 10.18632/oncotarget.10064 EDN: WSHXMH
- Jia W, Whitehead RN, Griffiths L, et al. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn’s disease? FEMS Microbiol Lett. 2010;310(2):138–144. doi: 10.1111/j.1574-6968.2010.02057.x EDN: NZHSDD
- Mclellan P, Auger S, Goudiaby MT, et al. Faecalibacterium diversity in the gut microbiome of Crohn’s disease patients. United European Gastroenterol J. 2025;13(8):1480–1490. doi: 10.1002/ueg2.70023 EDN: BIMWZB
- Lopez-Siles M, Khan TM, Duncan SH, et al. Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. Appl Environ Microbiol. 2012;78(2):420–428. doi: 10.1128/AEM.06858-11
- Chen SJ, Zhang DY, Wu X, et al. Washed microbiota transplantation for Crohn’s disease: A metagenomic, metatranscriptomic, and metabolomic-based study. World J Gastroenterol. 2024;30(11):1572–1587. doi: 10.3748/wjg.v30.i11.1572 EDN: ZQAJFF
- Basha OM, Hafez RA, Salem SM, et al. Impact of gut microbiome alteration in ulcerative colitis patients on disease severity and outcome. Clin Exp Med. 2023;23(5):1763–1772. doi: 10.1007/s10238-022-00917-x EDN: ZGEJBY
- Xu J, Liang R, Zhang W, et al. Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J Diabetes. 2020;12(3):224–236. doi: 10.1111/1753-0407.12986
- Chasov V, Gilyazova E, Ganeeva I, et al. Gut microbiota modulation: a novel strategy for rheumatoid arthritis therapy. Biomolecules. 2024;14(12):1653. doi: 10.3390/biom14121653 EDN: XAUQBS
- Vural M, Gilbert B, Üstün I, et al. Mini-review: human microbiome and rheumatic diseases. Front Cell Infect Microbiol. 2020;10:491160. doi: 10.3389/fcimb.2020.491160 EDN: NDUHNO
- Xu X, Zhou J, Xie H, et al. Immunomodulatory mechanisms of the gut microbiota and metabolites on regulatory T cells in rheumatoid arthritis. Front Immunol. 2025;16:1610254. doi: 10.3389/fimmu.2025.1610254 EDN: OJZIUJ
- Cui X, Ye L, Li J, et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep. 2018;8(1):635. doi: 10.1038/s41598-017-18756-2 EDN: YFTRZB
- Simadibrata DM, Auliani S, Widyastuti PA, et al. The gut microbiota profile in heart failure patients: A systematic review. J Gastrointestin Liver Dis. 2023;32(3):393–401. doi: 10.15403/jgld-4779 EDN: RFIIMA
- Zheng T, Meng C, Lv Z, et al. The critical role of Faecalibacterium prausnitzii in cardiovascular diseases. Rev Cardiovasc Med. 2025;26(3):26740. doi: 10.31083/RCM26740 EDN: WIRVXH
- Luo Y, Chang G, Yu G, et al. Unveiling the negative association of Faecalibacterium prausnitzii with ischemic stroke severity, impaired prognosis and pro-inflammatory markers. Heliyon. 2024;10(5):e26651. doi: 10.1016/j.heliyon.2024.e26651 EDN: ZVHCUF
- Moran-Ramos S, Macias-Kauffer L, López-Contreras BE, et al. A higher bacterial inward BCAA transport driven by Faecalibacterium prausnitzii is associated with lower serum levels of BCAA in early adolescents. Mol Med. 2021;27(1):108. doi: 10.1186/s10020-021-00371-7 EDN: MRVHGT
- Hensen T, Thiele I. Metabolic modeling links gut microbiota to metabolic markers of Parkinson’s disease. Gut Microbes. 2025;17(1):2554195. doi: 10.1080/19490976.2025.2554195 EDN: SGDEEA
- Rasoulian P, Akhgarjand C, Houjaghani H, et al. Gut dysbiosis in multiple sclerosis patients: a comparative analysis in fecal samples. Sci Rep. 2025;15(1):36009. doi: 10.1038/s41598-025-19998-1 EDN: QREUDN
- Knuesel T, Mohajeri MH. The role of the gut microbiota in the development and progression of major depressive and bipolar disorder. Nutrients. 2021;14(1):37. doi: 10.3390/nu14010037 EDN: CKNSZM
- Ma J, Sun L, Liu Y, et al. Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer. BMC Microbiol. 2020;20(1):82. doi: 10.1186/s12866-020-01739-1 EDN: CMZSFO
Supplementary files




